NCT06227585View on ClinicalTrials.gov

Feasibility Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Surgery
Interventions
DEVICE

REVEAL 475 System

The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration.

DRUG

Bevonescein

All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.

Trial Locations (1)

92093

RECRUITING

Jacobs Medical Center at UC San Diego Health, San Diego

Sponsors
All Listed Sponsors
lead

Alume Biosciences, Inc.

INDUSTRY

NCT06227585 - Feasibility Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery | Biotech Hunter | Biotech Hunter